Pharmacologically assisted treatment of opioid-dependent youth

Pediatric Drugs

Volumn 15, Issue 6, 2013, Pages 449-458

  Pecoraro, Anna ^a,b   Fishman, Marc ^c,d,e   Ma, Michelle ^f   Piralishvili, Gvantsa ^g   Woody, George E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Delaware Valley Node   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Mountain Manor Treatment Center   (United States)

^e Clinical Trials Network   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g Center for Mental Health and the Prevention of Addiction   (Georgia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; NALOXONE; NALTREXONE;

ADOLESCENT DISEASE; ANXIETY; ARTICLE; CLINICAL DECISION MAKING; COGNITIVE DEFECT; CONSTIPATION; COORDINATION; DETOXIFICATION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; FLUID RETENTION; HUMAN; LIVER TOXICITY; LOEFFLER PNEUMONIA; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDLINE; NAUSEA; OPIATE ADDICTION; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QT PROLONGATION; RELAPSE; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; SYSTEMATIC REVIEW;

ADOLESCENT; ANALGESICS, OPIOID; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY;

EID: 84890510398     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0041-5     Document Type: Article

References (60)

1. UNODC. World drug report 2011. Geneva. http://www.unodc.org/unodc/en/ data-and-analysis/WDR-2011.html.
2. Gahr M, Freudenmann RW, Hiemke C, et al. "Krokodil" revival of an old drug with new problems. Subst Use Misuse. 2012;47(7):861-3.
3. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future: national survey results on drug use, 1975-2010. Bethesda: National Institute on Drug Abuse; 2009.
4. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national survey results on drug use, 1975-2005: vol 1, secondary students (NIH publication no. 06-5883). Bethesda: National Institute on Drug Abuse; 2006.
5. SAMHSA. The NSDUH report: patterns and trends in nonmedical prescription pain reliever use: 2002-2005. Rockville: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2007.
6. SAMHSA. Results from the 2006 national survey on drug use and health: national findings. Rockville: SAMHSA; 2007.
7. Epstein DH, Phillips KA, Preston KL. Opioids. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins Health; 2011. p. 161-90.
8. Hasin D, Nunes E, Meydan J. Comorbidity of alcohol, drug and psychiatric disorders: epidemiology. In: Kranzler HR, Tinsley JA, editors. Dual diagnosis and psychiatric treatment: substance abuse and comorbid disorders. New York: Marcel Dekker Inc.; 2004. p. 1-33.
9. Rodríguez-Llera MC, Domingo-Salvany A, Brugal MT, et al. Psychiatric comorbidity in young heroin users. Drug Alcohol Depend. 2006;84(1):48-55.
10. Subramaniam GA, Stitzer MA, Woody GE. Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend. 2009;99:141-9.
11. Lankenau SE, Teti M, Silva K, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37-44 (Epub 2011/06/22).
12. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003-11.
13. Wu L, Blazer DG, Li T, Woody GW. Treatment use and barriers among adolescents with prescription opioid use disorders: 2005-2008. Addict Behav. 2011;36(12):1233-9.
14. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12(5):448-53.
15. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973-81.
16. Pecoraro A, Woody GE. Medication-assisted treatment for opioid dependence: making a difference in prisons. F1000 Med Rep. 2011;3:1.
17. WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 2009. http://www.who.int/substanceabuse/ publications/opioiddependenceguidelines.pdf.
18. Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS): 2010. Admissions. Rockville: Substance Abuse and Mental Health Services Administration; 2010.
19. Fudala PJ, Woody GE. Recent advances in the treatment of opiate addiction. Curr Psychiatry Rep. 2004;6:339-46.
20. Smyth BP, Fagan J, Kernan K. Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. J Subst Abuse Treat. 2012;42(1):35-44.
21. Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescents. Cochrane Database Syst Rev. 2009;2:CD007210.
22. Lehmann WX. The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. NIDA Monograph. 1973;8:82-3.
23. Gowling LR, Ali RI. The place of detoxification in treatment of opioid dependence. Curr Opin Psychiatry. 2006;19(3):266-70.
24. Gandhi DH, Jaffe JH, McNary S, et al. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction. 2003;98(4):453-62.
25. Minozzi S, Amato L, Davoli M. Detoxification treatments for opiate dependent adolescents. Cochrane Database Syst Rev. 2009;2:CD006749.
26. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA. 1965;193(8):646-50.
27. Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005;(3):CD003409.
28. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
29. Zanis DA, Woody GE. One year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257-60.
30. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer; 1991.
31. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049-56.
32. Millman RB, Khuri ET, Nyswander ME. Therapeutic detoxification of adolescent heroin addicts. Ann N Y Acad Sci. 1978;311:153-64.
33. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther. 1996;276(2):449-59.
34. Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. 1997;45(1-2):81-91.
35. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 Suppl):S13-27.
36. Reckitt Benkiser. Further US RB Pharmaceuticals announcement. 2012 [cited 2012 October 1]. http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2. aspx?pageid=1332&cc=GB.
37. Smyth BP, Fagan J, Kernan K. Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. J Subst Abuse Treatment. 2012;42(1):35-44.
38. Bell J, Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review. Drug Alcohol Rev. 2006;25:167-71.
39. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology. 2006;189(1):37-46.
40. ®). Addiction. 2007;102(8):1164-5.
41. Resnick RB, editor. A practitioner's experience with naltrexone. In: Proceedings of the 29th annual scientific conference of the American Society of Addiction Medicine; 1998; New Orleans
42. Sevarino KA, Kosten TR. Naltrexone for initiation and maintenance of opiate abstinence. In: Dean R, Bilsky EJ, Negus SS, editors. Opiate receptors and antagonists: from bench to clinic. New York: Humana; 2009. p. 227-45.
43. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind. placebo-controlled, multicenter randomised trial. Lancet. 2011;377(9776):1506- 13.
44. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108-15.
45. Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol. 2003;8(3):337-42.
46. Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105:1669-76.
47. Department of Health. Guidance for the pharmacological management of substance misuse among young people. London: Department of Health; 2009 http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-106429.pdf.
48. College of Physicians and Surgeons of Ontario. Methadone maintenance guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2005.
49. College of Physicians and Surgeons of Ontario. Methadone maintenance guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2011 http://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf.
50. Code of Federal Regulations, Title 42, section 8. Conditions for distribution and use of methadone products for the treatment of opioid addiction. http://www.dpt.samhsa.gov/regulations/legreg.aspx.
51. Drug Addiction Treatment Act of 2000. Title XXXV, section 3502 of the Children's Health Act of 2000. AKA PL 106-310. http://buprenorphine.samhsa.gov/ fulllaw.html.
52. Rowan A, Fudala P, Mulligan J. The medical management of adolescent heroin dependence. Curr Psychiatry Rep. 2000;2(6):527-30.
53. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
54. ® tablets.
55. Saxon AJ, Miotto K. Methadone maintenance. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott & Williams Wilkins; 2011. p. 419-36.
56. Methadone hydrochloride Intensol™ (Oral concentrate, USP) prescribing information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid= d0e6a966-179a-45e0-8444-4c1b8523f8d2.
57. Tompkins DA, Strain EC. Buprenorphine in the treatment of opioid dependence. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott & Williams Wilkins; 2011. p. 437-56.
58. ® prescribing information. http://www.suboxone.com/pdfs/SuboxonePI.pdf.
59. Harrison E, Petrakis I. Naltrexone pharmacotherapy. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Lippincott Williams & Wilkins: Philadelphia; 2011. p. 447-65.
60. ® (naltrexone for extended release injectable suspension) prescribing information. http://www.vivitrol.com/Content/pdf/ prescribing-info.pdf.